Monday 12 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
91.47% 101.32% 106.10% 81.71%

+8 more TTM periods

Piotroski F-Score
8 8 7 7
ROA
9.53% 8.58% 8.45% 7.74%
ROIC
12.98% 12.12% 10.48% 9.90%
Return on Tangible Assets
48.56% 52.93% 67.16% 52.61%
Average Days of Receivables
97.99 89.61 95.05 86.15
Free Cash Flow per Share
18.84 15.92 15.06 21.45
Free Cash Flow
10,175.00 8,597.00 8,100.00 11,539.00
Other line items

Show all line items

Columns are period end dates